Abivax
ABVX | NASDAQ
$83.61
-$3.97 (-4.53%)
At close: Nov 16, 2026, 4:00 PM ET
$83.90
+$0.29 (+0.35%)
After-hours:
Nov 16, 2026, 7:58 PM ET
Abivax Company Profile
Company profile explainedCompany Profile
Abivax S.A., operating as ABIVAX Société Anonyme, is a French pharmaceutical firm focused on the discovery and optimization of therapeutic drugs for inflammatory, infectious, and oncological diseases. A cornerstone of their product pipeline is ABX464, which is currently undergoing Phase IIb clinical trials for ulcerative colitis, Crohn's Disease, and COVID-19. This compound is also being evaluated in Phase IIa studies for rheumatoid arthritis and has successfully completed Phase IIa trials demonstrating viral remission in patients with HIV. Additionally, the company is advancing ABX 196, an immune-boosting candidate, through Phase 1/2 clinical trials targeting hepatocellular cancer. Abivax also conducts research initiatives for conditions like Dengue fever, influenza, and respiratory syncytial virus. The company has secured license agreements with key French scientific bodies, including the National Centre for Scientific Research, the University of Montpellier, and the Institut Curie. Founded in 2013, Abivax S.A. maintains its headquarters in Paris, France.
Key Executives
| Name | Position |
|---|---|
| Marc de Garidel | Chief Executive Officer & Director |
| Didier Blondel | EVice President, Chief Financial Officer & Board Secretary |
| Chris Rabbat | Chief Medical Officer |
| David Zhang | Chief Strategy Officer |
| Heather Dean | Global Head of Sales, Accounts & Commercial Operations |
| Hema Keshava | Senior Vice President of Finance |
| Ida Hatoum | Chief People & Compliance Officer |
| Ivan Nunez-Pacheco | Global Head of Patient Services |
| James Berger | Global Head of Marketing |
| Jeffrey N. Haas | Global Head of Market Access & Pricing |
| Jerome Denis | Executive Vice President of Process Development & Manufacturing |
| Keith Fournier | Senior Vice President of Global Regulatory Affairs |
| Kevin Shan | Vice President & Global Head of Biometrics |
| Mary Mantock | Senior VP & Global Head of Regulatory Affairs |
| Maurus de la Rosa | Senior Vice President of Research |
| Michael Nesrallah | Chief Commercial Officer |
| Patrick Malloy | Senior VP & Head of Investor Relations |
| Pierre Courteille | Chief Business Officer |
| Timothy Kelly | Chief Technical Officer |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| Sep 21, 2026 | F-6EF | Filing |
| Sep 21, 2026 | 6-K | Filing |
| Aug 14, 2026 | SC 13G/A | [Amend] Statement of acquisition of beneficial own... |
| Aug 13, 2026 | SC 13G/A | [Amend] Statement of acquisition of beneficial own... |
| Jul 06, 2026 | SC 13D/A | [Amend] Filing |
| Jul 02, 2026 | 6-K | Filing |
| Jul 02, 2026 | 424B5 | Filing |
| Jul 01, 2026 | FWP | Filing |
| Jun 30, 2026 | FWP | Filing |
| Jun 30, 2026 | 424B5 | Filing |
Abivax
| Country | France |
| IPO Date | Oct 20, 2023 |
| Industry | Biotechnology |
| Sector | Healthcare |
| Employees | 80 |
| CEO | Marc de Garidel |
Contact Details
7-11 Boulevard Haussmann Paris,
IF 75009 France
Stock Details
| Ticker Symbol | ABVX |
| Exchange | NASDAQ |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| CIK Code | 0001956827 |
| CUSIP Number | 00370M103 |
| ISIN Number | US00370M1036 |
| SIC Code | 2834 |
Recent News
- 14 days ago / globenewswire.comAbivax to Participate in Upcoming Fall Investor Conferences
- 1 month ago / seekingalpha.comCedar Grove Capital Q3 2026 Portfolio Update
- 2 months ago / seekingalpha.comAbivax: Priced Right Ahead Of 2 Make-Or-Break Catalysts
- 2 months ago / benzinga.comThese Analysts Slash Their Forecasts On Abivax Following H1 Results
- 2 months ago / globenewswire.comAbivax Presents Business Updates and First Half 2026 Financial Results
- 2 months ago / benzinga.comAccenture, Abivax and 3 Stocks to Watch Heading Into Monday
- 2 months ago / zacks.com4 Biotech Stocks to Watch as Potential Takeover Targets
- 2 months ago / benzinga.comAbivax Earnings Are Imminent; These Most Accurate Analysts Revise Forecasts Ahead Of Earnings Call
- 2 months ago / zacks.comAbivax SA Sponsored ADR (ABVX) Upgraded to Buy: Here's Why
- 4 months ago / seekingalpha.comAbivax: Obefazimod Goes The Distance And So Does My Buy Rating
Add to Watchlist
Select watchlists to add or remove ABVX